MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 592339 | Name: Sanazole

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sanazole is a 3-nitrotriazole cpd. It affects the human cervical cancer cell line.

Chemical Structure

Sanazole
Sanazole
CAS#104958-90-9

Theoretical Analysis

MedKoo Cat#: 592339

Name: Sanazole

CAS#: 104958-90-9

Chemical Formula: C7H11N5O4

Exact Mass: 229.0811

Molecular Weight: 229.20

Elemental Analysis: C, 36.68; H, 4.84; N, 30.56; O, 27.92

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Sanazole; AK 2123; AK-2123; AK2123
IUPAC/Chemical Name
1H-1,2,4-Triazole-1-acetamide, N-(2-methoxyethyl)-3-nitro-
InChi Key
YKDRHKCETNMLHL-UHFFFAOYSA-N
InChi Code
InChI=1S/C7H11N5O4/c1-16-3-2-8-6(13)4-11-5-9-7(10-11)12(14)15/h5H,2-4H2,1H3,(H,8,13)
SMILES Code
O=C(NCCOC)CN1N=C([N+]([O-])=O)N=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 229.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Sreeja S, Krishnan Nair CK. Tumor control by hypoxia-specific chemotargeting of iron-oxide nanoparticle - Berberine complexes in a mouse model. Life Sci. 2018 Feb 15;195:71-80. doi: 10.1016/j.lfs.2017.12.036. Epub 2017 Dec 28. PubMed PMID: 29289560. 2: Zeng YC, Wu R, Xiao YP, Xin Y, Chi F, Xing R, Xue M, Wang NQ. Radiation enhancing effects of sanazole and gemcitabine in hypoxic breast and cervical cancer cells in vitro. Contemp Oncol (Pozn). 2015;19(3):236-40. doi: 10.5114/wo.2015.51820. Epub 2015 Jun 2. PubMed PMID: 26557765; PubMed Central PMCID: PMC4631282. 3: Sreeja S, Nair CK. Anticancer Property of Iron Oxide Nanoparticle-Drug Complexes: An In Vitro Study. J Environ Pathol Toxicol Oncol. 2015;34(3):183-9. PubMed PMID: 26349601. 4: Nair GG, Nair CK. Sanazole directed targeting of silver nanoparticle drug complex to tumor mass: a preclinical investigation in murine model. J Cancer Res Ther. 2014 Oct-Dec;10(4):979-84. doi: 10.4103/0973-1482.148705. PubMed PMID: 25579540. 5: Cherdyntseva NV, Ivanova AA, Ivanov VV, Cherdyntsev E, Nair CK, Kagiya TV. Ascorbic acid glucoside reduces neurotoxicity and glutathione depletion in mouse brain induced by nitrotriazole radiosensitazer. J Cancer Res Ther. 2013 Jul-Sep;9(3):364-9. doi: 10.4103/0973-1482.119303. PubMed PMID: 24125967. 6: Zeng YC, Yu L, Xiao YP, Xin Y, Wang NQ, Zhang XY, Zhao L. Radiation enhancing effects with the combination of sanazole and irinotecan in hypoxic HeLa human cervical cancer cell line. J BUON. 2013 Jul-Sep;18(3):713-6. PubMed PMID: 24065488. 7: Getoff N. Vitamin C: electron emission, free radicals and biological versatility. In Vivo. 2013 Sep-Oct;27(5):565-70. Review. PubMed PMID: 23988889. 8: Yamazaki H, Nakamura S, Nishimura T, Kodani N, Tsubokura T, Kimoto T, Sihomi H, Aibe N, Yoshida K, Koizumi M, Kagiya T. Hypofractionated stereotactic radiotherapy with the hypoxic sensitizer AK-2123 (sanazole) for reirradiation of brain metastases: a preliminary feasibility report. Anticancer Res. 2013 Apr;33(4):1773-6. PubMed PMID: 23564833. 9: Yamazaki H, Nakamura S, Nishimura T, Okabe H, Aibe N, Yoshida K, Kagiya T. Intensity-modulated radiation therapy with hypoxic sensitizer AK-2123 (sanazole) for glioblastoma multiforme using simultaneous integrated boost technique. Anticancer Res. 2013 Apr;33(4):1685-8. PubMed PMID: 23564816. 10: Yamazaki H, Nakamura S, Kobayashi K, Tsubokura T, Kodani N, Aibe N, Yoshida K, Kagiya T, Koizumi M, Yamada K. Feasibility trial for daily oral administration of the hypoxic sensitizer AK-2123 (Sanazole) in radiotherapy. Anticancer Res. 2013 Feb;33(2):643-6. PubMed PMID: 23393361. 11: Mathur A, Mallia MB, Banerjee S, Sarma HD, Pillai MR. Preparation and evaluation of a ⁹⁹mTcN-PNP complex of sanazole analogue for detecting tumor hypoxia. Bioorg Med Chem Lett. 2013 Mar 1;23(5):1394-7. doi: 10.1016/j.bmcl.2012.12.079. Epub 2013 Jan 4. PubMed PMID: 23375795. 12: Hassan MA, Furusawa Y, Zhao QL, Takasaki I, Feril LB Jr, Tachibana K, Kudo N, Minemura M, Sugiyama T, Kondo T. Differential cytotoxicity and sonosensitization by sanazole: effect of cell type and acoustic parameters. J Med Ultrason (2001). 2011 Apr;38(2):65-72. doi: 10.1007/s10396-010-0295-2. Epub 2011 Jan 5. PubMed PMID: 27278421. 13: Sakabe T, Murata H, Konishi E, Koto K, Horie N, Matsui T, Sawai Y, Yamazaki H, Kagiya TV, Kubo T. High Efficacy of Preoperative Low-Dose Radiotherapy with Sanazole (AK-2123) for Extraskeletal Ewing's Sarcoma: A Case Report. Sarcoma. 2011;2011. pii: 185465. doi: 10.1155/2011/185465. Epub 2010 Sep 6. PubMed PMID: 20871855; PubMed Central PMCID: PMC2943094. 14: Yu DY, Zhao QL, Wei ZL, Shehata M, Kondo T. Enhancement of hyperthermia-induced apoptosis by sanazole in human lymphoma U937 cells. Int J Hyperthermia. 2009 Aug;25(5):364-73. doi: 10.1080/02656730902967418. PubMed PMID: 19551546. 15: Yu DY, Zhao QL, Wei ZL, Nomura T, Kashiwakura I, Kagiya TV, Kondo T. Enhancement of radiation-induced apoptosis of human lymphoma U937 cells by sanazole. Apoptosis. 2009 May;14(5):655-64. doi: 10.1007/s10495-009-0329-7. PubMed PMID: 19259823. 16: Dobrowsky W, Huigol NG, Jayatilake RS, Kizilbash NI, Okkan S, Kagiya TV, Tatsuzaki H. AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cancer cervix: initial results of an IAEA multicentre randomized trial. J Cancer Res Ther. 2005 Apr-Jun;1(2):75-8. PubMed PMID: 17998631. 17: Ullal SD, Shenoy KK, Pai MR, Chowta MN, Adiga SM, Dinesh M, Kamath A, Kotian MS, Pai DK. Safety and radiosensitizing efficacy of sanazole (AK 2123) in oropharyngeal cancers: randomized controlled double blind clinical trial. Indian J Cancer. 2006 Oct-Dec;43(4):151-5. PubMed PMID: 17192685. 18: Dobrowsky W, Huigol NG, Jayatilake RS, Kizilbash NI, Okkan S, Kagiya VT, Tatsuzaki H. AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: results of an IAEA multicentre randomised trial. Radiother Oncol. 2007 Jan;82(1):24-9. Epub 2006 Dec 11. PubMed PMID: 17161478. 19: Sugie C, Shibamoto Y, Ito M, Ogino H, Suzuki H, Uto Y, Nagasawa H, Hori H. Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo. J Radiat Res. 2005 Dec;46(4):453-9. PubMed PMID: 16394636. 20: Alam A, Rapthap CC, Singha LI, Sharan RN, Singh V. Radiomodulatory effect of liposome encapsulated AK-2123 on tumor in mice exposed to hepatocarcinogen. Mol Cell Biochem. 2005 Mar;271(1-2):139-50. PubMed PMID: 15881665.

View History

Orotidine

Orotidine

Featured